Active Trials Open to Enrollment
Primary Ciliary Dyskinesia Foundation Registry
Description: Individuals with a confirmed diagnosis of PCD can consent to participate in a registry of patients. This repository of de-identified data can be used for clinical research to benefit those affected by the disease.
Genentech
Description: A Phase 1C, Open label Multicenter study to evaluate the safety, tolerability and activity of Inhaled GDC-6988 in patient with muco-obstructive disease. For individuals without cystic fibrosis or primary ciliary dyskinesia, GDC-6988 functions as an inhaled mucolytic agent by activating TMEM16A, which enhances calcium-induced anion transport and increases mucus hydration and clearance.
United State Bronchiectasis and NTM Research Registry: A COPD Foundation Initiative.
Description: The Bronchiectasis and NTM Research Registry is a consolidated database of non-Cystic Fibrosis (non-CF) Bronchiectasis and/or NTM patients from multiple clinical institutions across the United States. The goal of the Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of non-CF Bronchiectasis and/or NTM lung disease.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension.
Description: researchers are evaluating if nebulized clofazimine can treat patients with MAC lung disease that is not clearing with usual therapy.